Sollpura

Novel, biotechnology-derived pancreatic enzyme replacement therapy for the potential treatment of exocrine pancreatic insufficiency due to cystic fibrosis and other conditions.

Learn more about Sollpura

Blisibimod

B-cell activating factor (BAFF) inhibitor for the potential treatment of IgA nephropathy.

Learn more about Blisibimod

LATEST NEWS

Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura.

READ MORE

Anthera Pharmaceuticals Announces Receipt of Nasdaq Listing Determination Notice and Plans Appeal.

READ MORE